News & Insights: Announcement

Analysis reveals that over a 16-year period, $46 billion in U.S. public funding generated dozens of new tools for fighting HIV, TB and other global threats; boosted economic performance at home and abroad; and is likely to spur $102 billion in industry investments Over the last 16 years, U.S. government funding for research and development (R&D) targeting global health challenges supported dozens of breakthrough innovations while generating billions of dollars in economic benefits, both global and domestic, and spurring a surge of industry investments, according to a new analysis from the Global Health Technologies Coalition (GHTC) and Policy Cures Research (PCR). “Public funding for global health R&D is small, relative to the incredible returns it provides for fighting neglected and emerging diseases like malaria, HIV, tuberculosis, Ebola and COVID-19 — and for stocking the pipeline with many promising new technologies,” said Dr. Kristie Mikus, GHTC’s executive director. “The innovations emerging from this work are important for advancing health and opportunity globally and for addressing America’s increasing vulnerability to infectious diseases.” Dr. Nick Chapman, CEO of PCR, said, “Our analysis shows that the $46 billion invested by the U.S. government between 2007 and 2022 has not only delivered a steady stream of new drugs, vaccines and prevention tools, but has also supported basic research that is expected to attract an additional $102 billion investment from industry.” The report, Doing Well by Doing Good, looks at the return on investment from federal funding for global health R&D that flows through agencies such as the National Institutes of Health, Biomedical Advanced Research and Development Authority, the U.S. Agency for International Development, and the U.S. Centers for Disease Control and Prevention. This funding helps to support work targeting historically neglected diseases such as malaria, HIV and tuberculosis (TB); more recently emerging threats that include COVID-19, Ebola, chikungunya and mpox; and sexual and reproductive health issues. The report notes that new tools are urgently needed because these challenges cause a massive loss of life around the world, impede economic progress in low- and middle-income countries, and pose a growing threat to Americans — especially with climate change facilitating the spread of disease.  For example, in the fight against neglected and emerging infectious diseases (other than COVID-19), the report found the funding contributed to the development of 67 new health technologies that have been approved since 1999. This includes 12 new products for fighting Ebola, which continues to spark new outbreaks; 12 for TB, a resurgent disease fueled by an alarming spread of drug-resistant strains; and 11 for malaria, which is once again on the rise globally and recently caused a surprising spate of locally acquired cases in the U.S.The report found the investments also are supporting a product development pipeline for neglected and emerging diseases that now includes 261 promising innovations in late-stage development. Many carry the potential to deliver major benefits in reducing the human and economic toll of these threats.  New global health tools now available or close to fruition that benefited from recent U.S. government investments include: A new drug, pretomanid, whose addition to a treatment regimen for TB has dramatically improved outcomes and reduced costs for treating patients infected with drug-resistant strains of the disease. Switching all patients with drug-resistant TB to pretomanid-based regimens could generate global health care cost savings of $740 million annually.  Two new long-acting HIV prevention options have the potential to transform global HIV prevention efforts by offering an alternative to daily pills for at-risk groups. Long-acting cabotegravir, delivered via a single bi-monthly injection, could avert 45% of new infections in the U.S. and up to 28% of potential future HIV infections in low- and middle-income countries. The dapivirine vaginal ring, a monthly product offering discreet protection, is another breakthrough option for use by women at high risk of infection. The U.S. government’s multi-agency Operation Warp Speed supported development of four COVID-19 vaccines that have since been deployed around the world. These vaccines contributed to saving 14.4 million lives in the first year of the pandemic alone. Also, between December 2020 and March 2022, they played a prominent role in the estimated $895 billion in direct health care costs savings linked to vaccination.Powerful new monoclonal antibodies or mAbs have emerged for fighting Ebola and malaria. Two approved mAbs for treating Ebola were found to significantly decrease mortality, to 11% for one of the drugs and 6% for the other, compared to 54% in untreated patients. Meanwhile, three promising mAbs for preventing malaria are in clinical development. There is already evidence for one of these mAbs indicating a potential to reduce infections by 54%–75% in communities where malaria emerges as a seasonal threat. The report also notes that U.S. investments in global health R&D are delivering considerable economic benefits globally and domestically.  From 2007 to 2022, U.S. funding supported R&D capacity and product manufacturing capabilities in 43 low- and middle-income countries along with health innovations that can reduce the financial burden of neglected and emerging infectious diseases. For example, in countries where malaria is common, new drugs and vaccines can dramatically reduce the costs of managing the disease, which can consume up to 8% of a family’s budget and reduce national GDP by 1.3%. In the United States, the report estimates that from 2007 to 2022, the $46 billion in public spending on global health R&D created 600,000 new jobs, generated $104 billion in economic activity and supported basic research endeavors that are on track to catalyze $102 billion in additional industry investments. And it’s the gift that keeps on giving. By supporting basic research that will continue to inspire health innovations for years to come, the report finds that it’s likely the $46 billion in public funding ultimately will generate $255 billion for the American economy — a six-fold return on investment. (A companion analysis from GHTC available here explores the funding impact on a state-by-state level, which includes stimulating tens of thousands of jobs in top research states like Maryland, Massachusetts, California, Virginia, North Carolina, Washington state, New York, New Jersey, Pennsylvania and Georgia.)  The report points out that Americans also benefit because funding for global health R&D is delivering tools for threats that are increasingly viewed as potential domestic risks. For example, the report notes that climate change is facilitating the spread of insect-borne pathogens into the continental U.S., including Chagas disease, dengue, Zika, chikungunya and malaria.“The irony is that despite producing blockbuster returns, public funding for global health R&D is not keeping pace with growing needs and rising risks,” said Dr. Mikus. “R&D funding for emerging threats largely has been reactive — mainly focused on emergencies like Ebola, Zika and COVID-19 — and R&D budgets for neglected diseases actually dropped 11% in 2022. We encourage policymakers to look at global health R&D as one of the best investments a government can make, right up there with roads, schools and national defense.”  ### About the Global Health Technologies Coalition The Global Health Technologies Coalition (GHTC) works to save and improve lives by encouraging the research and development of essential health technologies. We bring together more than 45 nonprofit organizations, academic institutions, and aligned businesses to advance policies to accelerate the creation of new drugs, vaccines, diagnostics, and other tools that bring healthy lives within reach for all people. About Policy Cures Research Policy Cures Research is an independent, not-for-profit, research and policy organisation providing strategic analysis and decision-making tools for those involved in the creation of new health technologies for neglected diseases, emerging infectious diseases and sexual & reproductive health issues. Its focus is on providing governments, funders, researchers and civil society organisations with the insights they need to make optimal R&D policy and funding decisions for diseases affecting the world’s most vulnerable populations. For more information, please contact: Katy Lenard at klenard@burness.com or +1 301-280-5719 

With G7 and G20 nations set to convene later this year under the respective presidencies of Italy and Brazil, GHTC is calling upon policymakers to robustly fund R&D partnerships for pandemic preparedness, establish a global medical countermeasures platform, support investments to strengthen local R&D capacity globally, advance R&D for key priorities like antimicrobial resistance and climate resiliency, and improve equitable access through regulatory strengthening and prioritizing the R&D needs of underserved populations. G7/G20 2024 Priorities This year’s G7 Italian and Brazilian G20 presidencies will largely continue to focus on priorities that have emerged post-COVID, including pandemic preparedness, prevention, and response and building a more fit for purpose global health architecture; strengthening local capacity, especially manufacturing; and placing a bigger emphasis on climate and health. Although the initial response to the pandemic ignited a surge in political will across all spectrums to accelerate R&D and to do so in more geographically diverse areas, challenges persist in achieving equity and access. The momentum and investment in the necessary global architecture reform and capacity building efforts are already starting to wane. At the same time, antimicrobial resistance (AMR) has been dubbed as the “silent pandemic,” creating an urgent need for R&D and the deployment of safe and innovative new antibiotics. The following are Global Health Technologies’ (GHTC) recommendations to the G7 and G20 to address these concerns.  1. Financing pandemic prevention, preparedness, and response (PPPR)Fully and sustainably finance public-private R&D and access partnerships for strategic health products crucial during a future health emergency or pandemic, including committing $80 million to FIND’s 100 Day Mission (100 DM) framework for diagnostics and $1.5 billion to fulfill the remaining financing needs for Coalition for Epidemic Preparedness’s (CEPI) 100DM strategy for vaccines, and supporting Unitaid, and others for therapeutics including oxygen therapy.Agree on a plan to fully and sustainably finance the Pandemic Fund to enable it to reach its financing target of $10.5 billion per year in response to the high need and demand for support of pandemic preparedness and prevention efforts in low- and middle-income countries (LMICs), beginning with increased support for a robust resource mobilization effort for the Pandemic Fund, to be concluded in Q4 of 2024.Develop and endorse a global pandemic response financing playbook for medical countermeasures (MCMs) access that is rapid, flexible and reflects a network of partnerships.2. Equity in healthInvest and support national and regional regulatory bodies, ensuring that quality-assured and safe products are able to reach those who need them most, especially in LMICs. Ensure that the specific end-to-end R&D needs of women, children, and other vulnerable populations are addressed, including through: Specifying target product profiles for health technologies that address the needs of vulnerable populations and investing in therapeutic formulations for children and pregnant people.Providing technical support to countries to facilitate equitable distribution and uptake of new tools through institutions such as the World Health Organization (WHO). Engaging with primary healthcare providers, communities, and civil society in the design and delivery of health technologies to ensure the interventions meet the needs and priorities of local populations 3. Increase access to medical countermeasuresEstablish and adopt an equitable end-to-end MCM platform guided by human rights principles, focusing on the needs of all, particularly those in LMICs, through sustainable financing, addressing R&D needs, and implementing mechanisms for equitable access. Facilitate collaboration with stakeholders, including the Medicines Patent Pool, to expedite licensing and technology transfer. Prioritize a patient- and human-centered approach with meaningful LMIC and regional body representation in governance. Commit to the development of a shared access framework for public R&D spending during inter-pandemic periods, in consultation with LMICs, industry, and relevant stakeholders, to include consistent clauses within funding agreements to ensure equitable, affordable access to products for LMICs at every stage of R&D. Support the coordination of vaccine manufacturing networks to service clinical trials and routine supplies in inter-pandemic and pandemic periods.Facilitate agreement between key stakeholders, countries and funders on how sustainable stockpiles of (experimental) vaccines, therapeutics, and diagnostics can be created to enable a rapid response to new outbreaks. 4. Strengthen local capacityStrengthen local capacity through support for R&D hubs, distributed manufacturing, and clinical trial infrastructure in LMICs. Support regionally-led plans for economically viable vaccine, diagnostics, therapeutics manufacturing.Manufacturing investments must be coupled with commitments by private-sector companies and governments to step up support for technology transfer, technical assistance to local manufacturers for quality systems, regulatory authorization, market entry, and workforce development so that new manufacturing capacities have the equipment, expertise, know-how, and power to produce and deliver new innovations safely and rapidly at scale.Support preferential procurement policies for regionally manufactured products from global procurers such as Gavi, Global Fund, UNICEF, and Unitaid. Promote knowledge sharing with collaborative tracking and monitoring, and enhance accountability through transparency and robust enforcement mechanisms for traceability of countermeasures.Commit to develop globally accessible online prototype libraries of diagnostics, therapeutics, and vaccines for priority viral and bacterial families, and for disease X, in coordination with the WHO’s updated priority viral family list.Accelerate clinical trials for determining product safety and effectiveness and systematically include community engagement plans in clinical study protocols.  Establish reference standards for diagnostics early in disease outbreaks and clinical trials.5. Climate and antimicrobial resistanceJoin up efforts to strengthen climate and pandemic resilience and improve health outcomes in an agenda for action and investment. Support the adoption of data-driven strategies to prevent and treat climate-sensitive (e.g. vector-borne) disease as part of measures aimed to adapt to climate change, and ensure that health tools are always available to all populations affected by climate change. Invest in R&D that integrates scientific disciplines to enhance the development of intelligently designed, quality-assured, novel and improved antimicrobials, alternative biologics, diagnostics, vaccines, and other health technologies to address drug-resistant bacterial, viral, parasitic, and fungal microorganisms. There are few new antimicrobials in clinical development and declining private investment, and we must take urgent action to support the limited pipeline for antimicrobials and new therapeutics.Increase investment into push and pull incentives with public health–driven selection criteria and strong stewardship and access requirements, in particular contributing to existing global efforts such as the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator, or CARB-X, and the Global Antibiotic Research & Development Partnership, or GARDP, at the earliest opportunity and within reasonable and feasible timelines.Provide ongoing support to the Global AMR R&D Hub in its work providing countries and investors with the latest AMR R&D landscape that helps address market gaps. The Hub should also pave the way for efficient deployment of tailor-made incentives for R&D and facilitate global discussion on priorities and opportunities for increasing investments in R&D.